Latest Announcements

Huntington's Disease, Parkinson's Disease, Investor Announcement

Prana Appoints David Stamler as Chief Medical Officer to Lead Clinical Development

David Stamler, M.D., has joined Prana Biotechnology (ASX PBT, NASDAQ PRAN) as Chief Medical Officer and Senior Vice President, Clinical Development, based in San Francisco.

 

Alzheimer's Disease, Parkinson's Disease, Investor Announcement

Prana’s Anti-Parkinsonian compound PBT434 presented at 13th International Conference for Alzheimer’s & Parkinson’s Diseases

Prana today announced a scientific presentation demonstrating pre-clinical evidence for Prana’s PBT434 as a first-in-class disease modifying therapy for the treatment of Parkinsonian movement disorders that will be featured at the 13th International Conference for Alzheimer’s and Parkinson’s Diseases in Vienna from 29 March 2 April 2017.

Multimedia

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"